| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | -71.15% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | 1054.07% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | 765.55% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | 1342.59% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | 477.03% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | 477.03% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | 188.52% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | 1054.07% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 4516.27% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 2785.17% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/27/2018 | 1919.62% | Stifel | $2.5 → $7 | Upgrades | Hold → Buy |
| 07/13/2018 | 3362.2% | SunTrust Robinson Humphrey | → $12 | Initiates Coverage On | → Buy |
| 06/06/2018 | — | Wells Fargo | Upgrades | Market Perform → Outperform | |
| 04/12/2018 | 1919.62% | Laidlaw & Co. | → $7 | Initiates Coverage On | → Buy |
What is the target price for MEI Pharma (MEIP)?
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Jefferies on February 8, 2023. The analyst firm set a price target for $0.10 expecting MEIP to fall to within 12 months (a possible -71.15% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MEI Pharma (MEIP)?
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Jefferies, and MEI Pharma downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
Is the Analyst Rating MEI Pharma (MEIP) correct?
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a downgraded with a price target of $0.40 to $0.10. The current price MEI Pharma (MEIP) is trading at is $0.35, which is out of the analyst's predicted range.